Key facts
- This page summarizes Chas McKhann's Form 4 filing for Silk Road Medical Inc.
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Sep 2024, 20:19.
Chas McKhann - 17 Sep 2024 Form 4 Insider Report for Silk Road Medical Inc
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 17 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Sep 2024, 20:19:27 UTC
- Prior SEC filing
- 05 Mar 2024
- Next SEC filing
- 21 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mhairi Jones, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chas McKhann filed Form 4 for Silk Road Medical Inc on 18 Sep 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SILK
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -722,396
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 17 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
SILK
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,299,042
- Change %
- Price
- $0.000000
- Shares after
- 1,299,042
- Date
- 17 Sep 2024
- Ownership
- Direct
- Footnotes
- F3
SILK
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -1,299,042
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 17 Sep 2024
- Ownership
- Direct
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Chas McKhann is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The reported shares are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
Footnote F2
Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) $27.50 per unit in cash (the "Merger Consideration") and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
Footnote F3
Immediately prior to the effective time of the merger, certain RSUs subject to the achievement of performance-based criteria, or PSUs, were deemed achieved and certified by the Issuer's compensation committee.
Footnote F4
Pursuant to the Merger Agreement, each PSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the PSUs, less applicable taxes and authorized deductions.